Compare Fox Corp Class B (FOX) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

FOX trades at $55.93, down 0.09% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 beating expectations of $1.44, and fundamentals show robust revenue growth to $16.30 billion in 2025 and a net income margin of 13.88%. Analyst consensus is a buy with a price target of $84.75, implying significant upside. A dividend of $0.29 per share is scheduled for payment on September 23, 2026.

The outlook for FOX is positive based on solid fundamentals and analyst optimism, but risks include a projected decline in net income margin to 9.83% in 2026 and bearish technical indicators. The stock offers value with a P/E of 14.56 and growth potential, though investors should monitor earnings consistency and market sentiment shifts.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.